APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchLyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection include China Biologic Products, Inc., Takeda Pharmaceutical, Shenzhen Weiguang Biological Products, Taibang Biologic Group, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Shanghai RAAS, Pacific Shuanglin Bio-pharmacy, Nanjing Pharmacare Co.,Ltd and Grifols, S.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Company

China Biologic Products, Inc.

Takeda Pharmaceutical

Shenzhen Weiguang Biological Products

Taibang Biologic Group

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Shanghai RAAS

Pacific Shuanglin Bio-pharmacy

Nanjing Pharmacare Co.,Ltd

Grifols, S.A.

Hualan Biological Engineering Inc.

Harbin Pacific Biopharmaceutical

Sinopharm Group Co., Ltd.

Boya Bio-Pharmaceutical Group Co., Ltd.

Bayer AG

Baxter International Inc.

Octapharma AG

CSL Behring

ADMA Biologics, Inc.

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Type

5g

2.5g

1.25g

Others

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Application

Hospitals

Clinics

Others

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Trends Table 2. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Drivers Table 3. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Opportunities and Challenges Table 4. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Restraints Table 5. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Manufacturers Table 9. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturers, Product Type & Application Table 13. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 5g Table 17. Major Manufacturers of 2.5g Table 18. Major Manufacturers of 1.25g Table 19. Major Manufacturers of Others Table 20. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (k units) Table 22. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2027-2032) & (k units) Table 23. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2021-2026) Table 24. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2027-2032) Table 25. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type (2021-2026) & (k units) Table 27. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type (2027-2032) & (k units) Table 28. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2021-2026) Table 29. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Others Table 33. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (k units) Table 35. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2027-2032) & (k units) Table 36. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026) Table 37. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2027-2032) Table 38. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application (2021-2026) & (k units) Table 40. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application (2027-2032) & (k units) Table 41. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2021-2026) Table 42. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2027-2032) Table 43. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026) & (k units) Table 45. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2021-2026) Table 46. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 50. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2027-2032) & (k units) Table 51. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 53. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2027-2032) & (k units) Table 60. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2021-2026) Table 64. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2027-2032) Table 65. China Biologic Products, Inc. Company Information Table 66. China Biologic Products, Inc. Business Overview Table 67. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 69. China Biologic Products, Inc. Recent Development Table 70. Takeda Pharmaceutical Company Information Table 71. Takeda Pharmaceutical Business Overview Table 72. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 74. Takeda Pharmaceutical Recent Development Table 75. Shenzhen Weiguang Biological Products Company Information Table 76. Shenzhen Weiguang Biological Products Business Overview Table 77. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 79. Shenzhen Weiguang Biological Products Recent Development Table 80. Taibang Biologic Group Company Information Table 81. Taibang Biologic Group Business Overview Table 82. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 84. Taibang Biologic Group Recent Development Table 85. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information Table 86. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Business Overview Table 87. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 89. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Development Table 90. Shanghai RAAS Company Information Table 91. Shanghai RAAS Business Overview Table 92. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 94. Shanghai RAAS Recent Development Table 95. Pacific Shuanglin Bio-pharmacy Company Information Table 96. Pacific Shuanglin Bio-pharmacy Business Overview Table 97. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 99. Pacific Shuanglin Bio-pharmacy Recent Development Table 100. Nanjing Pharmacare Co.,Ltd Company Information Table 101. Nanjing Pharmacare Co.,Ltd Business Overview Table 102. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 104. Nanjing Pharmacare Co.,Ltd Recent Development Table 105. Grifols, S.A. Company Information Table 106. Grifols, S.A. Business Overview Table 107. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 109. Grifols, S.A. Recent Development Table 110. Hualan Biological Engineering Inc. Company Information Table 111. Hualan Biological Engineering Inc. Business Overview Table 112. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 114. Hualan Biological Engineering Inc. Recent Development Table 115. Harbin Pacific Biopharmaceutical Company Information Table 116. Harbin Pacific Biopharmaceutical Business Overview Table 117. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 119. Harbin Pacific Biopharmaceutical Recent Development Table 120. Sinopharm Group Co., Ltd. Company Information Table 121. Sinopharm Group Co., Ltd. Business Overview Table 122. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 124. Sinopharm Group Co., Ltd. Recent Development Table 125. Boya Bio-Pharmaceutical Group Co., Ltd. Company Information Table 126. Boya Bio-Pharmaceutical Group Co., Ltd. Business Overview Table 127. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 129. Boya Bio-Pharmaceutical Group Co., Ltd. Recent Development Table 130. Bayer AG Company Information Table 131. Bayer AG Business Overview Table 132. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 134. Bayer AG Recent Development Table 135. Baxter International Inc. Company Information Table 136. Baxter International Inc. Business Overview Table 137. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 139. Baxter International Inc. Recent Development Table 140. Octapharma AG Company Information Table 141. Octapharma AG Business Overview Table 142. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 144. Octapharma AG Recent Development Table 145. CSL Behring Company Information Table 146. CSL Behring Business Overview Table 147. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 149. CSL Behring Recent Development Table 150. ADMA Biologics, Inc. Company Information Table 151. ADMA Biologics, Inc. Business Overview Table 152. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 154. ADMA Biologics, Inc. Recent Development Table 155. Key Raw Materials Table 156. Raw Materials Key Suppliers Table 157. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors List Table 158. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Customers List Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Image Figure 2. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (2021-2032) & (k units) Figure 5. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 5g Image Figure 9. 2.5g Image Figure 10. 1.25g Image Figure 11. Others Image Figure 12. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2021-2032) Figure 15. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Others Image Figure 21. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2032) Figure 24. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2021-2032) Figure 27. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 29. U.S. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 34. Germany Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 41. China Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2032) Figure 49. Brazil Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 60. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 62. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 5g
  • 2.5g
  • 1.25g
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • China Biologic Products, Inc.
  • Takeda Pharmaceutical
  • Shenzhen Weiguang Biological Products
  • Taibang Biologic Group
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Shanghai RAAS
  • Pacific Shuanglin Bio-pharmacy
  • Nanjing Pharmacare Co.,Ltd
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Harbin Pacific Biopharmaceutical
  • Sinopharm Group Co., Ltd.
  • Boya Bio-Pharmaceutical Group Co., Ltd.
  • Bayer AG
  • Baxter International Inc.
  • Octapharma AG
  • CSL Behring
  • ADMA Biologics, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Dynamics
  1. 2.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Trends
  2. 2.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Drivers
  3. 2.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Opportunities and Challenges
  4. 2.4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Restraints
3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Manufacturers
  1. 3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturers, Product Type & Application
  7. 3.7 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Tier 1, Tier 2, and Tier 3
4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Type
  1. 4.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Type Introduction
  2. 4.1.1 5g
  3. 4.1.2 2.5g
  4. 4.1.3 1.25g
  5. 4.1.4 Others
  6. 4.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type
  7. 4.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2032)
  9. 4.2.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2021-2032)
  10. 4.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type
  11. 4.3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type (2021-2032)
  13. 4.3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2021-2032)
5 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Application
  1. 5.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application
  6. 5.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2032)
  8. 5.2.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2032)
  9. 5.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application
  10. 5.3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application (2021-2032)
  12. 5.3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2021-2032)
6 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region
  1. 6.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region
  1. 7.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region
  2. 7.1.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032)
  8. 7.2.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032)
  11. 7.3.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 China Biologic Products, Inc.
  2. 8.1.1 China Biologic Products, Inc. Company Information
  3. 8.1.2 China Biologic Products, Inc. Business Overview
  4. 8.1.3 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  6. 8.1.5 China Biologic Products, Inc. Recent Developments
  7. 8.2 Takeda Pharmaceutical
  8. 8.2.1 Takeda Pharmaceutical Company Information
  9. 8.2.2 Takeda Pharmaceutical Business Overview
  10. 8.2.3 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  12. 8.2.5 Takeda Pharmaceutical Recent Developments
  13. 8.3 Shenzhen Weiguang Biological Products
  14. 8.3.1 Shenzhen Weiguang Biological Products Company Information
  15. 8.3.2 Shenzhen Weiguang Biological Products Business Overview
  16. 8.3.3 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  18. 8.3.5 Shenzhen Weiguang Biological Products Recent Developments
  19. 8.4 Taibang Biologic Group
  20. 8.4.1 Taibang Biologic Group Company Information
  21. 8.4.2 Taibang Biologic Group Business Overview
  22. 8.4.3 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  24. 8.4.5 Taibang Biologic Group Recent Developments
  25. 8.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  26. 8.5.1 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  30. 8.5.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Shanghai RAAS
  32. 8.6.1 Shanghai RAAS Company Information
  33. 8.6.2 Shanghai RAAS Business Overview
  34. 8.6.3 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  36. 8.6.5 Shanghai RAAS Recent Developments
  37. 8.7 Pacific Shuanglin Bio-pharmacy
  38. 8.7.1 Pacific Shuanglin Bio-pharmacy Company Information
  39. 8.7.2 Pacific Shuanglin Bio-pharmacy Business Overview
  40. 8.7.3 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  42. 8.7.5 Pacific Shuanglin Bio-pharmacy Recent Developments
  43. 8.8 Nanjing Pharmacare Co.,Ltd
  44. 8.8.1 Nanjing Pharmacare Co.,Ltd Company Information
  45. 8.8.2 Nanjing Pharmacare Co.,Ltd Business Overview
  46. 8.8.3 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  48. 8.8.5 Nanjing Pharmacare Co.,Ltd Recent Developments
  49. 8.9 Grifols, S.A.
  50. 8.9.1 Grifols, S.A. Company Information
  51. 8.9.2 Grifols, S.A. Business Overview
  52. 8.9.3 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  54. 8.9.5 Grifols, S.A. Recent Developments
  55. 8.10 Hualan Biological Engineering Inc.
  56. 8.10.1 Hualan Biological Engineering Inc. Company Information
  57. 8.10.2 Hualan Biological Engineering Inc. Business Overview
  58. 8.10.3 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  60. 8.10.5 Hualan Biological Engineering Inc. Recent Developments
  61. 8.11 Harbin Pacific Biopharmaceutical
  62. 8.11.1 Harbin Pacific Biopharmaceutical Company Information
  63. 8.11.2 Harbin Pacific Biopharmaceutical Business Overview
  64. 8.11.3 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  66. 8.11.5 Harbin Pacific Biopharmaceutical Recent Developments
  67. 8.12 Sinopharm Group Co., Ltd.
  68. 8.12.1 Sinopharm Group Co., Ltd. Company Information
  69. 8.12.2 Sinopharm Group Co., Ltd. Business Overview
  70. 8.12.3 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  72. 8.12.5 Sinopharm Group Co., Ltd. Recent Developments
  73. 8.13 Boya Bio-Pharmaceutical Group Co., Ltd.
  74. 8.13.1 Boya Bio-Pharmaceutical Group Co., Ltd. Company Information
  75. 8.13.2 Boya Bio-Pharmaceutical Group Co., Ltd. Business Overview
  76. 8.13.3 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  78. 8.13.5 Boya Bio-Pharmaceutical Group Co., Ltd. Recent Developments
  79. 8.14 Bayer AG
  80. 8.14.1 Bayer AG Company Information
  81. 8.14.2 Bayer AG Business Overview
  82. 8.14.3 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  84. 8.14.5 Bayer AG Recent Developments
  85. 8.15 Baxter International Inc.
  86. 8.15.1 Baxter International Inc. Company Information
  87. 8.15.2 Baxter International Inc. Business Overview
  88. 8.15.3 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  90. 8.15.5 Baxter International Inc. Recent Developments
  91. 8.16 Octapharma AG
  92. 8.16.1 Octapharma AG Company Information
  93. 8.16.2 Octapharma AG Business Overview
  94. 8.16.3 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  96. 8.16.5 Octapharma AG Recent Developments
  97. 8.17 CSL Behring
  98. 8.17.1 CSL Behring Company Information
  99. 8.17.2 CSL Behring Business Overview
  100. 8.17.3 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  102. 8.17.5 CSL Behring Recent Developments
  103. 8.18 ADMA Biologics, Inc.
  104. 8.18.1 ADMA Biologics, Inc. Company Information
  105. 8.18.2 ADMA Biologics, Inc. Business Overview
  106. 8.18.3 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  108. 8.18.5 ADMA Biologics, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Value Chain Analysis
  2. 9.1.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Production Mode & Process
  6. 9.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors
  9. 9.2.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst